GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000838031 | Stomach | WIM | RNA splicing | 23/426 | 434/18723 | 1.66e-04 | 4.08e-03 | 23 |
GO:003311941 | Stomach | WIM | negative regulation of RNA splicing | 5/426 | 25/18723 | 2.17e-04 | 4.84e-03 | 5 |
GO:000037731 | Stomach | WIM | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 17/426 | 320/18723 | 1.12e-03 | 1.63e-02 | 17 |
GO:000039831 | Stomach | WIM | mRNA splicing, via spliceosome | 17/426 | 320/18723 | 1.12e-03 | 1.63e-02 | 17 |
GO:190331231 | Stomach | WIM | negative regulation of mRNA metabolic process | 8/426 | 92/18723 | 1.18e-03 | 1.68e-02 | 8 |
GO:000037531 | Stomach | WIM | RNA splicing, via transesterification reactions | 17/426 | 324/18723 | 1.28e-03 | 1.77e-02 | 17 |
GO:1990830 | Stomach | WIM | cellular response to leukemia inhibitory factor | 8/426 | 94/18723 | 1.36e-03 | 1.86e-02 | 8 |
GO:19908231 | Stomach | WIM | response to leukemia inhibitory factor | 8/426 | 95/18723 | 1.46e-03 | 1.97e-02 | 8 |
GO:004348441 | Stomach | WIM | regulation of RNA splicing | 10/426 | 148/18723 | 2.10e-03 | 2.54e-02 | 10 |
GO:00506575 | Stomach | WIM | nucleic acid transport | 10/426 | 163/18723 | 4.21e-03 | 4.01e-02 | 10 |
GO:00506585 | Stomach | WIM | RNA transport | 10/426 | 163/18723 | 4.21e-03 | 4.01e-02 | 10 |
GO:00512365 | Stomach | WIM | establishment of RNA localization | 10/426 | 166/18723 | 4.79e-03 | 4.33e-02 | 10 |
GO:00159315 | Stomach | WIM | nucleobase-containing compound transport | 12/426 | 222/18723 | 5.02e-03 | 4.48e-02 | 12 |
GO:000838041 | Stomach | SIM | RNA splicing | 33/708 | 434/18723 | 1.20e-04 | 2.81e-03 | 33 |
GO:003311951 | Stomach | SIM | negative regulation of RNA splicing | 6/708 | 25/18723 | 2.74e-04 | 5.21e-03 | 6 |
GO:004348451 | Stomach | SIM | regulation of RNA splicing | 15/708 | 148/18723 | 4.97e-04 | 8.08e-03 | 15 |
GO:000037741 | Stomach | SIM | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 25/708 | 320/18723 | 5.21e-04 | 8.27e-03 | 25 |
GO:000039841 | Stomach | SIM | mRNA splicing, via spliceosome | 25/708 | 320/18723 | 5.21e-04 | 8.27e-03 | 25 |
GO:000037541 | Stomach | SIM | RNA splicing, via transesterification reactions | 25/708 | 324/18723 | 6.24e-04 | 9.29e-03 | 25 |
GO:000640311 | Stomach | SIM | RNA localization | 16/708 | 201/18723 | 4.15e-03 | 3.72e-02 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F7 | SNV | Missense_Mutation | novel | c.308N>A | p.Ser103Tyr | p.S103Y | P08709 | protein_coding | tolerated(0.17) | benign(0.028) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | | c.729N>G | p.Ile243Met | p.I243M | P08709 | protein_coding | deleterious(0.04) | benign(0.157) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | novel | c.1132N>A | p.Gly378Arg | p.G378R | P08709 | protein_coding | tolerated(0.22) | benign(0) | TCGA-AR-A2LJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
F7 | SNV | Missense_Mutation | rs749760143 | c.973N>A | p.Glu325Lys | p.E325K | P08709 | protein_coding | tolerated(0.05) | probably_damaging(0.933) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
F7 | insertion | Frame_Shift_Ins | novel | c.731_732insGGGAAAATGGGCAGGTCAGC | p.Asn244LysfsTer28 | p.N244Kfs*28 | P08709 | protein_coding | | | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | insertion | Frame_Shift_Ins | novel | c.757_758insGCAA | p.His253ArgfsTer29 | p.H253Rfs*29 | P08709 | protein_coding | | | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
F7 | insertion | In_Frame_Ins | novel | c.759_760insCCCAAGGCCGAATTGTGGGGGGCAAGG | p.His253_Cys254insProLysAlaGluLeuTrpGlyAlaArg | p.H253_C254insPKAELWGAR | P08709 | protein_coding | | | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
F7 | SNV | Missense_Mutation | | c.475N>C | p.Glu159Gln | p.E159Q | P08709 | protein_coding | deleterious(0.04) | benign(0.115) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
F7 | SNV | Missense_Mutation | novel | c.348N>C | p.Gln116His | p.Q116H | P08709 | protein_coding | deleterious(0.02) | probably_damaging(0.961) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | | c.160N>A | p.Val54Ile | p.V54I | P08709 | protein_coding | tolerated(0.2) | benign(0.01) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Vatreptacog alfa (activated) | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Factor viia | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Recombinant factor VIIa PEGylated liposomal | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | F-7TG | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | BAX-817 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 178103166 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | CB-813 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Activated recombinant FVII-albumin fusion protein | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 252166701 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Eptacog alfa intravenous | | |